– UK, Slough – Indivior PLC (LON: INDV / Nasdaq: INDV) today announced the appointment of Dr. David Wheadon (M.D.) to its Board as an Independent Non-Executive Director effective from June 1, 2024.
“We are delighted to announce David’s appointment as an Independent Non-Executive Director. David has extensive experience in the biopharmaceutical industry and expertise in global heath policy and regulatory affairs, product quality and patient safety. He will be a tremendous asset as we continue to focus on our purpose of pioneering life-transforming treatments for substance use disorders, serious mental illness and accidental overdose,” said Board chair, Graham Hetherington.
About Dr. David E. Wheadon
Dr. David Wheadon is a health policy leader and physician with over three decades of global experience in the pharmaceutical industry.
Dr. Wheadon served as SVP of global regulatory affairs, patient safety, and quality assurance at AstraZeneca Plc from December 2014 to July 2019. Before that, he was EVP, of research and advocacy at Juvenile Diabetes Research Foundation International Inc., from May 2013 to December 2014, and SVP, of scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America (PhRMA), from January 2009 to May 2013. Dr. Wheadon served as VP, of global pharmaceutical regulatory and medical science, and group VP, of global pharmaceutical regulatory affairs at Abbott Laboratories from 2005 to 2009. Before Abbott Laboratories,
Dr. Wheadon held senior regulatory and clinical development leadership positions at GlaxoSmithKline Plc and Eli Lilly and Company.
Dr. Wheadon received his M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts.
Dr. Wheadon is a Non-executive Independent Director of Sotera Health Company (Nasdaq: SHC), Vaxart, Inc (Nasdaq: VXRT), and ConnectiveRx. He also serves as a Board of Trustees of Mount Sinai Health System member. Before its recent acquisition by Bristol-Myers Squibb Company, Dr. Wheadon served as a Non-executive Independent Director of Karuna Therapeutics, Inc (NASDAQ: KRTX).
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for chronic conditions and co-occurring disorders of substance use disorder. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide.
SOURCE: https://www.indivior.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
